
ARE Stock Forecast & Price Target
ARE Analyst Ratings
Bulls say
Alexandria Real Estate Equities Inc. is well-positioned for growth supported by its significant presence in key life science markets, which is bolstered by a record $10.8 billion backlog and increasing public sector demand. The company's focus on purpose-built space for life science, agtech, and technology tenants aligns with emerging trends in biotechnology and technology sectors, enhancing its long-term profitability prospects. Additionally, lower interest rates and potential recovery in biotech valuations may accelerate demand for lab space, further underpinning a favorable outlook for the company's operations.
Bears say
Alexandria Real Estate Equities Inc faces a negative outlook primarily due to several detrimental factors affecting its financial performance, including a year-over-year decline tied to lower operational results and management fees. There are significant concerns regarding expected occupancy erosion and an oversupply of life science properties, compounded by stagnating demand and funding constraints in the life science sector, leading to adverse effects on development leasing and earnings growth. Additionally, external pressures such as government shutdowns and changes in research grant reimbursements further exacerbate the company’s challenging operational landscape, prompting revisions in revenue estimates for the near future.
This aggregate rating is based on analysts' research of Alexandria Real Estate Equities and is not a guaranteed prediction by Public.com or investment advice.
ARE Analyst Forecast & Price Prediction
Start investing in ARE
Order type
Buy in
Order amount
Est. shares
0 shares